Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDV/SOF + GS-9669 or RBV in HCV GT1 Cirrhotics
NCT01984294Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of radalbuvir in hepatitis C (HCV) (3 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Permanently Discontinuing Any Study Drug Due to an Adverse Event up to 8 weeks. Started Oct 2013; status: completed.
02
Drugs
radalbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01984294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01984294.